SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

MEI Pharma, Kyowa Kirin Highlight Updated Clinical Data From Phase 1b Study Of ME-401 On Intermittent Schedule in Patients with Follicular Lymphoma and Other B-cell Malignancies For ASCO: 83% Overall Response Rate

Benzinga · 05/13/2020 21:13